KBC Group
RYTM icon

KBC Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

KBC Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Hold
1,707
– – ﹤0.01% 1100
2025
Q4 		$183K Hold
1,707
– – ﹤0.01% 948
2025
Q3 		$172K Hold
1,707
– – ﹤0.01% 967
2025
Q2 		$108K Sell
1,707
-544
-24% -$33.3K ﹤0.01% 1155
2025
Q1 		$119K Hold
2,251
– – ﹤0.01% 1382
2024
Q4 		$126K Buy
2,251
+988
+78% +$54.6K ﹤0.01% 1396
2024
Q3 		$66K Hold
1,263
– – ﹤0.01% 1566
2024
Q2 		$52K Hold
1,263
– – ﹤0.01% 1590
2024
Q1 		$55K Hold
1,263
– – ﹤0.01% 1499
2023
Q4 		$58K Buy
1,263
+452
+56% +$14.3K ﹤0.01% 1415
2023
Q3 		$19K Buy
+811
New +$18.2K ﹤0.01% 1887

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

KBC Group's RYTM Position: Q1 2026 in Review

KBC Group held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 1,707 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

KBC Group first reported a position in RYTM in Q3 2023 and has held it in 11 quarters since. The position peaked at $183K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • KBC Group held 1,707 shares of Rhythm Pharmaceuticals worth $148K as of Q1 2026.
  • KBC Group left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1100 holding.
  • KBC Group first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Rhythm Pharmaceuticals position peaked at $183K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.